Rheumatic masqueraders: mimics of primary vasculitis - a case-based review

References

• Grayson PC, Ponte C, Suppiah R, et al. 2022 American college of rheumatology/European alliance of associations for rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis. 2022;81(3):309–314. doi: 10.1136/annrheumdis-2021-221794
   PubMed Web of Science ®Google Scholar
• Grayson PC, Ponte C, Suppiah R, et al. 2022 American college of rheumatology/EULAR classification criteria for Takayasu Arteritis. Arthritis & Rheumat. 2022;74(12):1872–1880. doi: 10.1002/art.42324
   PubMed Web of Science ®Google Scholar
• Ponte C, Grayson PC, Robson JC, et al. 2022 American college of rheumatology/EULAR classification criteria for giant cell arteritis. Arthritis & Rheumat. 2022;74(12):1881–1889. doi: 10.1002/art.42325
   PubMed Web of Science ®Google Scholar
• Robson JC, Grayson PC, Ponte C, et al. 2022 American college of rheumatology/European alliance of associations for rheumatology classification criteria for granulomatosis with polyangiitis. Arthritis & Rheumat. 2022;74(3):393–399. doi: 10.1002/art.41986
   PubMed Web of Science ®Google Scholar
• Suppiah R, Robson JC, Grayson PC, et al. 2022 American college of rheumatology/European alliance of associations for rheumatology classification criteria for microscopic polyangiitis. Ann Rheum Dis. 2022;81(3):321–326. doi: 10.1136/annrheumdis-2021-221796
   PubMed Web of Science ®Google Scholar
• Estrada-Veras JI, O’Brien KJ, Boyd LC, et al. The clinical spectrum of Erdheim-Chester disease: an observational cohort study. Blood Adv. 2017;1(6):357–366. doi: 10.1182/bloodadvances.2016001784
   PubMed Web of Science ®Google Scholar
• Cohen-Aubart F, Emile JF, Carrat F, et al. Phenotypes and survival in Erdheim-Chester disease: results from a 165-patient cohort. Am J Hematol. 2018;93(5):E114–E117. doi: 10.1002/ajh.25055
   PubMed Web of Science ®Google Scholar
• Haroche J, Charlotte F, Arnaud L, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012;120(13):2700–2703. doi: 10.1182/blood-2012-05-430140
   PubMed Web of Science ®Google Scholar
• Diamond EL, Durham BH, Haroche J, et al. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov. 2016;6(2):154–165. doi: 10.1158/2159-8290.CD-15-0913
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi: 10.1182/blood-2016-01-643569
   PubMed Web of Science ®Google Scholar
• Goyal G, Heaney ML, Collin M, et al. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood. 2020;135(22):1929–1945. doi: 10.1182/blood.2019003507
   PubMed Web of Science ®Google Scholar
• Serratrice J, Granel B, De Roux C, et al. “Coated aorta”: a new sign of Erdheim-Chester disease. J Rheumatol. 2000;27(6):1550–1553.
   PubMed Web of Science ®Google Scholar
• Haroche J, Arnaud L, Cohen-Aubart F, et al. Erdheim-Chester disease. Rheum Dis Clin North Am. 2013;39(2):299–311. doi: 10.1016/j.rdc.2013.02.011
   PubMed Web of Science ®Google Scholar
• Haroche J, Cluzel P, Toledano D, et al. Images in cardiovascular medicine. Cardiac involvement in Erdheim-Chester disease: magnetic resonance and computed tomographic scan imaging in a monocentric series of 37 patients. Circulation. 2009;119(25):e597–598. doi: 10.1161/CIRCULATIONAHA.108.825075
   PubMed Web of Science ®Google Scholar
• Goyal G, Young JR, Koster MJ, et al. The Mayo Clinic histiocytosis working group consensus statement for the diagnosis and evaluation of adult patients with histiocytic neoplasms: Erdheim-Chester disease, langerhans cell histiocytosis, and Rosai-Dorfman disease. Mayo Clin Proc. 2019;94(10):2054–2071. doi: 10.1016/j.mayocp.2019.02.023
   PubMed Web of Science ®Google Scholar
• Shenouda M, Riga C, Naji Y, et al. Segmental arterial mediolysis: a systematic review of 85 cases. Ann Vasc Surg. 2014;28(1):269–277. doi:10.1016/j.avsg.2013.03.003
   PubMed Web of Science ®Google Scholar
• Naidu SG, Menias CO, Oklu R, et al. Segmental arterial mediolysis: abdominal imaging of and disease course in 111 patients. AJR Am J Roentgenol. 2018;210(4):899–905. doi: 10.2214/AJR.17.18309
   PubMed Web of Science ®Google Scholar
• Skeik N, Olson SL, Hari G, et al. Segmental arterial mediolysis (SAM): systematic review and analysis of 143 cases. Vasc Med. 2019;24(6):549–563. doi: 10.1177/1358863X19873410
   PubMed Web of Science ®Google Scholar
• Peng KX, Davila VJ, Stone WM, et al. Natural history and management outcomes of segmental arterial mediolysis. J Vasc Surg. 2019;70(6):1877–1886. doi: 10.1016/j.jvs.2019.02.068
   PubMedGoogle Scholar
• Michael M, Widmer U, Wildermuth S, et al. Segmental arterial mediolysis: CTA findings at presentation and follow-up. AJR Am J Roentgenol. 2006;187(6):1463–1469. doi:10.2214/AJR.05.0281
   PubMed Web of Science ®Google Scholar
• Alhalabi K, Menias C, Hines R, et al. Imaging and clinical findings in segmental arterial mediolysis (SAM). Abdom Radiol (NY). 2017;42(2):602–611. doi:10.1007/s00261-016-0887-4
   PubMed Web of Science ®Google Scholar
• Malfait F, Francomano C, Byers P, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175(1):8–26. doi: 10.1002/ajmg.c.31552
   PubMed Web of Science ®Google Scholar
• Frank M, Adham S, Seigle S, et al. Vascular Ehlers-Danlos syndrome: long-term observational study. J Am Coll Cardiol. 2019;73(15):1948–1957. doi: 10.1016/j.jacc.2019.01.058
   PubMed Web of Science ®Google Scholar
• Shalhub S, Byers PH, Hicks KL, et al. A multi-institutional experience in vascular Ehlers-Danlos syndrome diagnosis. J Vasc Surg. 2020;71(1):149–157. doi: 10.1016/j.jvs.2019.04.487
   PubMed Web of Science ®Google Scholar
• Frank M, Albuisson J, Ranque B, et al. The type of variants at the COL3A1 gene associates with the phenotype and severity of vascular Ehlers-Danlos syndrome. Eur J Hum Genet. 2015;23(12):1657–1664. doi: 10.1038/ejhg.2015.32
   PubMed Web of Science ®Google Scholar
• Byers PH, Belmont J, Black J, et al. Diagnosis, natural history, and management in vascular Ehlers-Danlos syndrome. Am J Med Genet C Semin Med Genet. 2017;175(1):40–47. doi: 10.1002/ajmg.c.31553
   PubMed Web of Science ®Google Scholar
• Arora A, Wetter DA, Gonzalez-Santiago TM, et al. Incidence of leukocytoclastic vasculitis, 1996 to 2010: a population-based study in olmsted county, Minnesota. Mayo Clin Proc. 2014;89(11):1515–1524. doi:10.1016/j.mayocp.2014.04.015
   PubMed Web of Science ®Google Scholar
• Watts RA, Jolliffe VA, Grattan CE, et al. Cutaneous vasculitis in a defined population–clinical and epidemiological associations. J Rheumatol. 1998;25(5):920–924.
   PubMed Web of Science ®Google Scholar
• Garcia-Porrua C, Gonzalez-Gay MA. Comparative clinical and epidemiological study of hypersensitivity vasculitis versus henoch-schonlein purpura in adults. Semin Arthritis Rheum. 1999;28(6):404–412. doi:10.1016/S0049-0172(99)80006-7
   PubMed Web of Science ®Google Scholar
• Loricera J, Calvo-Rio V, Ortiz-Sanjuan F, et al. The spectrum of paraneoplastic cutaneous vasculitis in a defined population: incidence and clinical features. Medicine (Baltimore). 2013;92(6):331–343. doi: 10.1097/MD.0000000000000009
   PubMed Web of Science ®Google Scholar
• Sanchez-Guerrero J, Gutierrez-Urena S, Vidaller A, et al. Vasculitis as a paraneoplastic syndrome. Report of 11 cases and review of the literature. J Rheumatol. 1990;17(11):1458–1462.
   PubMed Web of Science ®Google Scholar
• Gibson LE, Su WP. Cutaneous vasculitis. Rheum Dis Clin North Am. 1995;21(4):1097–1113. doi:10.1016/S0889-857X(21)00487-7
   PubMed Web of Science ®Google Scholar
• Solans-Laque R, Bosch-Gil JA, Perez-Bocanegra C, et al. Paraneoplastic vasculitis in patients with solid tumors: report of 15 cases. J Rheumatol. 2008;35(2):294–304.
   PubMed Web of Science ®Google Scholar
• Zehnder P, Jenni W, Aeschlimann AG. Systemic vasculitis and solid tumors (epitheliomas). Rev Rhum Engl Ed. 1998;65(6):442.
   PubMedGoogle Scholar
• Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol. 2014;63(22):e57–185. doi: 10.1016/j.jacc.2014.02.536
   PubMed Web of Science ®Google Scholar
• Watts RA, Hatemi G, Burns JC, et al. Global epidemiology of vasculitis. Nat Rev Rheumatol. 2022;18(1):22–34. doi:10.1038/s41584-021-00718-8
   PubMed Web of Science ®Google Scholar
• Tan JA, Dehghan N, Chen W, et al. Mortality in ANCA-associated vasculitis: ameta-analysis of observational studies. Ann Rheum Dis. 2017;76(9):1566–1574. doi:10.1136/annrheumdis-2016-210942
   PubMed Web of Science ®Google Scholar
• Ternhag A, Cederstrom A, Torner A, et al. A nationwide cohort study of mortality risk and long-term prognosis in infective endocarditis in Sweden. PLoS One. 2013;8(7):e67519. doi:10.1371/journal.pone.0067519
   PubMed Web of Science ®Google Scholar
• Langlois V, Lesourd A, Girszyn N, et al. Antineutrophil cytoplasmic antibodies associated with infective endocarditis. Medicine (Baltimore). 2016;95(3):e2564. doi: 10.1097/MD.0000000000002564
   PubMed Web of Science ®Google Scholar
• Ying CM, Yao DT, Ding HH, et al. Infective endocarditis with antineutrophil cytoplasmic antibody: report of 13 cases and literature review. PLoS One. 2014;9(2):e89777. doi:10.1371/journal.pone.0089777
   PubMed Web of Science ®Google Scholar
• Mahr A, Batteux F, Tubiana S, et al. Brief report: prevalence of antineutrophil cytoplasmic antibodies in infective endocarditis. Arthritis & Rheumat. 2014;66(6):1672–1677. doi: 10.1002/art.38389
   PubMed Web of Science ®Google Scholar
• Boils CL, Nasr SH, Walker PD, et al. Update on endocarditis-associated glomerulonephritis. Kidney Int. 2015;87(6):1241–1249. doi:10.1038/ki.2014.424
   PubMed Web of Science ®Google Scholar
• Silverman ME, Upshaw CB Jr. Extracardiac manifestations of infective endocarditis and their historical descriptions. Am J Cardiol. 2007;100(12):1802–1807. doi:10.1016/j.amjcard.2007.07.034
   PubMed Web of Science ®Google Scholar
• Tous-Romero F, Delgado-Marquez AM, Gargallo-Moneva V, et al. Cutaneous vasculitis: a presentation with endocarditis to keep in mind. An Bras Dermatol. 2017;92(4):594–595. doi:10.1590/abd1806-4841.20176317
   PubMed Web of Science ®Google Scholar
• Peng H, Chen WF, Wu C, et al. Culture-negative subacute bacterial endocarditis masquerades as granulomatosis with polyangiitis (Wegener’s granulomatosis) involving both the kidney and lung. BMC Nephrol. 2012;13:174. doi: 10.1186/1471-2369-13-174
   PubMed Web of Science ®Google Scholar
• Conlon PJ, Jefferies F, Krigman HR, et al. Predictors of prognosis and risk of acute renal failure in bacterial endocarditis. Clin Nephrol. 1998;49(2):96–101.
   PubMed Web of Science ®Google Scholar
• Bonaci-Nikolic B, Andrejevic S, Pavlovic M, et al. Prolonged infections associated with antineutrophil cytoplasmic antibodies specific to proteinase 3 and myeloperoxidase: diagnostic and therapeutic challenge. Clin Rheumatol. 2010;29(8):893–904. doi:10.1007/s10067-010-1424-4
   PubMed Web of Science ®Google Scholar
• Uh M, McCormick IA, Kelsall JT. Positive cytoplasmic antineutrophil cytoplasmic antigen with PR3 specificity glomerulonephritis in a patient with subacute bacterial endocarditis. J Rheumatol. 2011;38(7):1527–1528. doi:10.3899/jrheum.101322
   PubMed Web of Science ®Google Scholar
• Deshayes S, Aouba A, Khoy K, et al. Hypocomplementemia is associated with worse renal survival in ANCA-positive granulomatosis with polyangiitis and microscopic polyangiitis. PLoS One. 2018;13(4):e0195680. doi:10.1371/journal.pone.0195680
   PubMed Web of Science ®Google Scholar
• Ten Hove D, Slart R, Sinha B, et al. (18)F-FDG PET/CT in infective endocarditis: indications and approaches for standardization. Curr Cardiol Rep. 2021;23(9):130. doi:10.1007/s11886-021-01542-y
   PubMed Web of Science ®Google Scholar
• Hubers SA, DeSimone DC, Gersh BJ, et al. Infective endocarditis: a contemporary review. Mayo Clin Proc. 2020;95(5):982–997. doi:10.1016/j.mayocp.2019.12.008
   PubMed Web of Science ®Google Scholar
• Brook I. Infective endocarditis caused by anaerobic bacteria. Arch Cardiovasc Dis. 2008;101(10):665–676. doi:10.1016/j.acvd.2008.08.008
   PubMed Web of Science ®Google Scholar
• Satoskar AA, Parikh SV, Nadasdy T. Epidemiology, pathogenesis, treatment and outcomes of infection-associated glomerulonephritis. Nat Rev Nephrol. 2020;16(1):32–50. doi:10.1038/s41581-019-0178-8
   PubMed Web of Science ®Google Scholar
• Bele D, Kojc N, Perse M, et al. Diagnostic and treatment challenge of unrecognized subacute bacterial endocarditis associated with ANCA-PR3 positive immunocomplex glomerulonephritis: a case report and literature review. BMC Nephrol. 2020;21(1):40. doi: 10.1186/s12882-020-1694-2
   PubMed Web of Science ®Google Scholar
• Van Gool IC, Kers J, Bakker JA, et al. Antineutrophil cytoplasmic antibodies in infective endocarditis: a case report and systematic review of the literature. Clin Rheumatol. 2022;41(10):2949–2960. doi: 10.1007/s10067-022-06240-w
   PubMed Web of Science ®Google Scholar
• Mustaquim D, Jones CM, Compton WM. Trends and correlates of cocaine use among adults in the United States, 2006-2019. Addict Behav. 2021;120:106950. doi:10.1016/j.addbeh.2021.106950
   PubMed Web of Science ®Google Scholar
• Marquez J, Aguirre L, Munoz C, et al. Cocaine-levamisole-induced vasculitis/vasculopathy syndrome. Curr Rheumatol Rep. 2017;19(6):36. doi:10.1007/s11926-017-0653-9
   PubMed Web of Science ®Google Scholar
• Nitro L, Pipolo C, Fadda GL, et al. Distribution of cocaine-induced midline destructive lesions: systematic review and classification. Eur Arch Otorhinolaryngol. 2022;279(7):3257–3267. doi: 10.1007/s00405-022-07290-1
   PubMed Web of Science ®Google Scholar
• Daggett RB, Haghighi P, Terkeltaub RA. Nasal cocaine abuse causing an aggressive midline intranasal and pharyngeal destructive process mimicking midline reticulosis and limited Wegener’s granulomatosis. J Rheumatol. 1990;17(6):838–840.
   PubMed Web of Science ®Google Scholar
• McGrath MM, Isakova T, Rennke HG, et al. Contaminated cocaine and antineutrophil cytoplasmic antibody-associated disease. Clin J Am Soc Nephrol. 2011;6(12):2799–2805. doi:10.2215/CJN.03440411
   PubMed Web of Science ®Google Scholar
• Lood C, Hughes GC. Neutrophil extracellular traps as a potential source of autoantigen in cocaine-associated autoimmunity. Rheumatology (Oxford). 2017;56(4):638–643. doi:10.1093/rheumatology/kew256
   PubMed Web of Science ®Google Scholar
• Pieterse E, van der Vlag J. Cracking the pathogenesis of cocaine-induced vasculitis. Rheumatology (Oxford). 2017;56(4):503–505. doi:10.1093/rheumatology/kew381
   PubMed Web of Science ®Google Scholar
• Peikert T, Finkielman JD, Hummel AM, et al. Functional characterization of antineutrophil cytoplasmic antibodies in patients with cocaine-induced midline destructive lesions. Arthritis Rheum. 2008;58(5):1546–1551. doi: 10.1002/art.23469
   PubMedGoogle Scholar
• Wiesner O, Russell KA, Lee AS, et al. Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastase as a diagnostic marker for cocaine-induced midline destructive lesions but not autoimmune vasculitis. Arthritis Rheum. 2004;50(9):2954–2965. doi: 10.1002/art.20479
   PubMed Web of Science ®Google Scholar
• Subesinghe S, van Leuven S, Yalakki L, et al. Cocaine and ANCA associated vasculitis-like syndromes - a case series. Autoimmun Rev. 2018;17(1):73–77. doi:10.1016/j.autrev.2017.11.011
   PubMed Web of Science ®Google Scholar
• Morcos MB, Lood C, Hughes GC. Demographic, clinical, and immunologic correlates among a cohort of 50 cocaine users demonstrating antineutrophil cytoplasmic antibodies. J Rheumatol. 2019;46(9):1151–1156. doi:10.3899/jrheum.180771
   PubMed Web of Science ®Google Scholar
• Pakalniskis MG, Berg AD, Policeni BA, et al. The many faces of granulomatosis with polyangiitis: a review of the head and neck imaging manifestations. AJR Am J Roentgenol. 2015;205(6):W619–629. doi: 10.2214/AJR.14.13864
   PubMed Web of Science ®Google Scholar
• Armengot M, Garcia-Lliberos A, Gomez MJ, et al. Sinonasal involvement in systemic vasculitides and cocaine-induced midline destructive lesions: diagnostic controversies. Allergy Rhinol (Providence). 2013;4(2):e94–99. doi:10.2500/ar.2013.4.0051
   PubMedGoogle Scholar
• Mirzaei A, Zabihiyeganeh M, Haqiqi A. Differentiation of cocaine-induced midline destructive lesions from ANCA-Associated vasculitis. Iran J Otorhinolaryngol. 2018;30(100):309–313.
   PubMedGoogle Scholar
• Khurana S, Chhoda A, Sahay S, et al. Pulmonary foreign body granulomatosis in a chronic user of powder cocaine. J Bras Pneumol. 2017;43(4):320–321. doi:10.1590/s1806-37562015000000269
   PubMed Web of Science ®Google Scholar
• Solomon N, Hayes J. Levamisole: a high performance cutting agent. Acad Forensic Pathol. 2017;7(3):469–476. doi:10.23907/2017.039
   PubMedGoogle Scholar
• Midthun KM, Nelson LS, Logan BK. Levamisole-a toxic adulterant in illicit drug preparations: a review. Ther Drug Monit. 2021;43(2):221–228. doi:10.1097/FTD.0000000000000851
   PubMed Web of Science ®Google Scholar
• Zwang NA, Van Wagner LB, Rose S. A case of levamisole-induced systemic vasculitis and cocaine-induced midline destructive lesion: a case report. J Clin Rheumatol. 2011;17(4):197–200. doi:10.1097/RHU.0b013e31821cb9d5
   PubMed Web of Science ®Google Scholar
• Fredericks C, Yon JR, Alex G, et al. Levamisole-induced necrosis syndrome: presentation and management. Wounds. 2017;29(3):71–76.
   PubMed Web of Science ®Google Scholar
• Trimarchi M, Bertazzoni G, Bussi M. Cocaine induced midline destructive lesions. Rhinology. 2014;52(2):104–111. doi:10.4193/Rhino13.112
   PubMed Web of Science ®Google Scholar
• Trimarchi M, Bussi M, Sinico RA, et al. Cocaine-induced midline destructive lesions - an autoimmune disease? Autoimmun Rev. 2013;12(4):496–500. doi:10.1016/j.autrev.2012.08.009
   PubMed Web of Science ®Google Scholar
• Raheemullah A, Melhem M, Andruska N. Cocaine cessation for levamisole-induced vasculitis: treating the underlying disease. J Clin Rheumatol. 2020;26(8):e276–e278. doi:10.1097/RHU.0000000000001123
   PubMed Web of Science ®Google Scholar
• Gross RL, Brucker J, Bahce-Altuntas A, et al. A novel cutaneous vasculitis syndrome induced by levamisole-contaminated cocaine. Clin Rheumatol. 2011;30(10):1385–1392. doi: 10.1007/s10067-011-1805-3
   PubMed Web of Science ®Google Scholar
• Abousy M, Sylvester S, Milek D, et al. Surgical management and outcomes of levamisole-induced vasculitis in a burn center: a case series. JAAD Case Rep. 2021;13:36–42. doi:10.1016/j.jdcr.2021.04.028
   PubMedGoogle Scholar
• Di Cosola M, Ambrosino M, Limongelli L, et al. Cocaine-induced midline destructive lesions (CIMDL): a real challenge in diagnosis. Int J Environ Res Public Health. 2021;18(15):7831. doi: 10.3390/ijerph18157831
   PubMed Web of Science ®Google Scholar
• Colletti G, Autelitano L, Chiapasco M, et al. Comprehensive surgical management of cocaine-induced midline destructive lesions. J Oral Maxillofac Surg. 2014;72(7):1395 e1391–1310. doi: 10.1016/j.joms.2014.03.013
   Web of Science ®Google Scholar